The last ‘SCImago Institutions Ranking’ classified the 3,000 best research institutions in the world. Harvard University tops the ranking, but the Catalan institute, is ranked second in Spain and among the best European research centres. Catalonia, and in particular Barcelona is consolidating its position as a biomedical science centre at international level.
For the first time in the world, a foetus having the spina bifida congenital disorder went through a new intra-uterus surgery technique. A medical team from Barcelona’s Vall d’Hebron Hospital operated on the foetus in its 24th week by placing a biological fabric on the spinal cord, in order to protect it from amniotic liquid and to ease the gap’s closing. The baby is now five months old and doctors are confident she may walk without any problems.
The latest technology and sustainability converge on the façade of the new Barça football school and residence, the new Masia. This cinematic façade will be used as new advertising support by FC Barcelona sponsors. A 1,460 m² led screen will do this with no overheads for the club.
The vaccine MVA-B against HIV gets a 90% immune response in its first test with humans. In addition, after a year, the vaccine proves to still be effective in 85% of the individuals. The vaccine is still a prototype but it shows a promising perspective. Soon it will be tested as well as a therapeutic vaccine, for people already infected with HIV-AIDS. The vaccine has been developed by the Spanish High Council of Scientific Research (CSIC), in collaboration with Barcelona’s Hospital Clínic and by Madrid’s Hospital Gregorio Marañón.
Between 2007 and 2010, Catalan research centres and private companies participated in a total of 1,047 projects funded by the Seventh Framework Programmes for Research and Technological Development of the European Union. In total, Catalan researchers have received 384 million euros from the EU in the last four years, which represents a 73% increase in relation to the previous programme, which ran from mid 2002 to 2006.
The study by the Bellvitge Biomedical Research Institute has managed to demonstrate that a molecule similar to glucose can cause the death of cancerous cells. The research would enable to shortly develop treatments for the alveolar rhabdomyosarcoma.
"This could mean a breakthrough in the fight against cancer," said the head of the study Juan Angel Recio from Barcelona-based Vall d’Hebron Research Institute.
The research results were published on the website of the prestigious journal 'Nature Chemistry' and will appear in the print edition as well. The Universitat de Girona is particularly strong in research related to water. The study opens a new path to develop new technologies to carry out artificial photosynthesis.
The innovative technology has a pencil to measure vital signs, an odour detector, a sound detector and two cameras. The Catalan Government's Fire Department and the French firemen from Marseille CEREM participate in the deisgn of the new device.
The Formula 1 circuit next to Barcelona, which hosts Spain’s Grand Prix, has been the stage of the fourth round of the ECO series 2011 race last Sunday, in which thirty electric and hybrid vehicles competed.
26 new knowledge-intensive companies have set their offices in Barcelona’s 22@district over the first half of this year. The innovation district has more than 1,500 companies and increased its turnover by 5.4% against the 2008 census.
The vineyards grow in a stony land and the grapes are produced by organic agriculture. The small and young company aims to kick off its third vintage, which is expected to produce 50,000 bottles of organically certified wine.
The Catalan pharmaceutical company is the world’s leader in blood-derived products. After expanding in the United States by purchasing Talecris, Grifols needed a larger headquarters. It moved to three interconnected buildings in Sant Cugat del Vallès, in Barcelona’s Metropolitan Area. From the new facilities, Grifols will investigate stem cells and Alzheimer’s.
Researchers from Barcelona’s Hospital Clínic find other indicators about the beginning of Alzheimer’s. They recommend using alternative biomarkers to get an early diagnosis.
The Catalan Government is benchmarked by the American company for using this technology that has enabled saving up to 20% of the costs, according to a representative from the CTIT.